CAR-T cell therapy: Advances in digestive system malignant tumors

被引:0
|
作者
Xu, Nan [1 ,2 ]
Wu, Zhonglin [2 ]
Pan, Jun [1 ]
Xu, Xiao [3 ,4 ]
Wei, Qiang [3 ]
机构
[1] Zhejiang Univ, Sch Med, Hangzhou 310058, Peoples R China
[2] Westlake Univ, Key Lab Integrated Oncol & Intelligent Med Zhejian, Hangzhou Peoples Hosp 1, Sch Med, Hangzhou 310006, Peoples R China
[3] Hangzhou Med Coll, Sch Clin Med, Hangzhou 310053, Peoples R China
[4] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310029, Peoples R China
来源
MOLECULAR THERAPY ONCOLOGY | 2024年 / 32卷 / 04期
关键词
SOLID TUMORS; ANTITUMOR-ACTIVITY; CANCER; RECEPTOR; TARGET; EFFICACY; COMPLEX; NKG2D; MUC1; HER2;
D O I
10.1016/j.omton.2024.200872
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant tumors of the digestive system have had a notoriously dismal prognosis throughout history. Immunotherapy, radiotherapy, surgery, and chemotherapy are the primary therapeutic approaches for digestive system cancers. The rate of recurrence and metastasis, nevertheless, remains elevated. As one of the immunotherapies, chimeric antigen receptor T cell (CAR-T) therapy has demonstrated a promising antitumor effect in hematologic cancer. Despite undergoing numerous clinical trials, the ineffective antitumor effect and adverse effects of CAR-T cell therapy in the treatment of digestive system cancers continue to impede its clinical translation. It is necessary to surmount the restricted options for targeting proteins, the obstacles that impede CAR-T cell infiltration into solid tumors, and the limited survival time in vivo. We examined and summarized the developments, obstacles, and countermeasures associated with CAR-T therapy in digestive system cancers. Emphasis was placed on the regulatory functions of potential antigen targets, the tumor microenvironment, and immune evasion in CAR-T therapy. Thus, our analysis has furnished an all-encompassing comprehension of CAR-T cell therapy in digestive system cancers, which will generate tremendous enthusiasm for subsequent in-depth research into CAR-T- based therapies in digestive system cancers.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Advances in CAR-T therapy for central nervous system tumors
    Zhou, Delian
    Zhu, Xiaojian
    Xiao, Yi
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [2] Advances in Universal CAR-T Cell Therapy
    Lin, Haolong
    Cheng, Jiali
    Mu, Wei
    Zhou, Jianfeng
    Zhu, Li
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
    Chen, Tong
    Wang, Mingzhao
    Chen, Yanchao
    Liu, Yutao
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [4] A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors
    Tschernia, Nicholas P.
    Khagi, Simon
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (09)
  • [5] A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors
    Nicholas P. Tschernia
    Simon Khagi
    Current Treatment Options in Oncology, 2020, 21
  • [6] CAR-T Cell Therapy for Solid Tumors
    Tony, Liz T.
    Stabile, Andrea
    Schauer, Marc P.
    Hudecek, Michael
    Weber, Justus
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2025,
  • [7] Research advances of nanoparticles for CAR-T therapy in solid tumors
    Chen, Bohan
    Gong, Liming
    Feng, Jing
    Jin, Mingji
    Chen, Liqing
    Gao, Zhonggao
    Huang, Wei
    CHINESE CHEMICAL LETTERS, 2024, 35 (09)
  • [8] Research advances of nanoparticles for CAR-T therapy in solid tumors
    Bohan Chen
    Liming Gong
    Jing Feng
    Mingji Jin
    Liqing Chen
    Zhonggao Gao
    Wei Huang
    Chinese Chemical Letters, 2024, 35 (09) : 98 - 108
  • [9] Recent Advances in CAR-T Therapy
    Ali, Meher Binte
    CANCER CONTROL, 2024, 31
  • [10] Recent advances and current challenges in CAR-T cell therapy
    Joy, R.
    Phair, K.
    O'Hara, R.
    Brady, D.
    BIOTECHNOLOGY LETTERS, 2024, 46 (01) : 115 - 126